华堂宁（多格列艾汀片）自进入国家医保药品目录后，已在中国建立了强大的医院渠道网络，Hualing Pharmaceutical-B (02552) announced that the company issued a written notice to Bayer Healthcare Co., Ltd. stating that it intends to transfer the commercialization responsibility of Huatangning, the company's first glucokinase activator developed to treat type 2 diabetes, to the company in China starting January 1, 2025.
The Zhitong Finance App learned that on November 22, Hualing Pharmaceutical-B (02552) announced that the company issued a written notice to Bayer Healthcare Co., Ltd. stating that it intends to transfer the commercialization responsibility of Huatangning, the company's first glucokinase activator developed to treat type 2 diabetes, to the company in China starting January 1, 2025. To achieve the transition, the company has the right and plans to terminate the agreement as of January 1, 2025. From the date of this announcement until the effective date of termination, Bayer and Company will continue to fulfill their obligations under the agreement and promise to launch a friendly, patient-centered transition plan. To support Huatangning's continued commercial sales in China, the company may seek other potential partners to commercialize Huatangning in China.
According to information, Hualing Pharmaceuticals and Bayer signed a strategic cooperation agreement on huatangning (dorzagliatin tablets, dorzagliatin) on August 17, 2020. Up to now, Hualing Pharmaceuticals has received a total of 1.5 billion yuan in milestone payments from Bayer. This capital will be used to build its own sales team and expand overseas business to further enhance Hualing Pharmaceutical's competitiveness in the field of global diabetes treatment. Previously, the cooperation model between Hualing Pharmaceuticals and Bayer was divided into five parts. The funds obtained were sufficient to cover the cost of building a self-owned sales team and bring additional profits to the company.
Since entering the national medical insurance drug catalogue, Huatangning (doglitin tablets) has established a strong hospital channel network in China, covering more than 2,000 hospitals, especially hospitals in cities such as Beijing, Tianjin, and Shanghai. This broad market coverage not only provides a solid market foundation for Hualing Pharmaceutical, but also lays a good foundation for upcoming medical insurance volume sales. Sales after medical insurance will further increase Huatangning's market penetration rate and bring good news to more patients with type 2 diabetes.
In addition, doglitin is rapidly increasing production capacity and speeding up its entry into hospitals and pharmacies across the country to benefit more patients. As the number of drug users continues to grow, the safety of Huatangning has been well verified, and its economic and social benefits have also been greatly improved, injecting confidence into the future development of Hualing Pharmaceutical.
